INTRODUCTION
============

The intestine is a unique tissue where a refined balance is maintained between immune responses and tolerance against a variety of environmental factors including microflora and food antigens. In the intestine, aberrant inflammatory responses can cause development of inflammatory bowel disease (IBD), which is characterized by two main clinical forms, Crohn\'s disease (CD) and ulcerative colitis (UC). Moreover, it was commonly assumed that intestinal inflammation was caused by a disruption in the balance between Th1 and Th2 cytokine responses. In addition, abnormal activation of Th17 cells has been implicated in the pathogenesis of CD. The number of Th1 cells and Th17 cells increased in the lamina propria of patients with IBD compared with healthy individuals, suggesting that a Th1/Th17 pathway may contribute to the development of IBD ([@B1]).

At steady state, the number and activity of effector T cells are tightly regulated by Foxp3^+^ regulatory (T~reg~) T cells, since excessive Th1 and Th17 responses can result in the gut inflammation. Foxp3^+^ T~reg~ cell has the ability to suppress inflammatory responses through the production of anti-inflammatory cytokines including IL-10 and transforming growth factor (TGF)-β, in addition to other mechanisms which can inhibit the function of antigen-presenting cells via expression of CTLA-4, LAG-3, CD39 and Nrp-1 ([@B2]). The transcription factor Foxp3 has been identified as a master regulator of T~reg~ cells. Indeed, loss of function mutations in Foxp3 causes IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) ([@B3]). Intestinal Foxp3^+^ T~reg~ cells produce a large amount of IL-10 compared with those present in other tissues and play an important role in the maintenance of the gut homeostasis ([@B4]). T~reg~ cell-derived IL-10 is thought to regulate the activity of intestinal myeloid cells.

Recently, several innate immune subsets have been reported to modulate the intestinal homeostasis through regulation of adaptive immune responses in mouse ([@B5]-[@B7]). In the intestine, activity of innate immune myeloid cells such as dendritic cells and macrophages is finely regulated by several mechanisms because the excessive and inadequate initiation of innate immunity leads to the development of IBD. Accordingly, patients with CD possess inappropriate or defective innate immune functions, including cytokine production, pathogen clearance, and recruitment of neutrophils. Genome-wide mapping has identified the genes and genetic loci that contribute to IBD susceptibility, including IL-10, IL-12p40, IL-23R and CARD9 ([@B8],[@B9]). Thus, intestinal innate immune cells are responsible for maintenance of the gut homeostasis, and dysregulation of activity of these cells lead to development of IBD through induction of colitogenic effector T cells.

This review focuses on a variety of murine innate immune subsets, which are responsible for maintenance of the gut homeostasis leading to prevention of intestinal inflammation, and human intestinal myeloid cells implicated in pathogenesis of IBD.

REGULATION OF ADAPTIVE IMMUNITY BY THE INTESTINAL INNATE IMMUNE SUBSETS
=======================================================================

The intestinal mononuclear phagocytes could be subdivided several subsets possessing different ability to maintain gut homeostasis either through promoting or preventing T cell responses ([@B10]-[@B13]), according to expression pattern of characteristic surface marker including CD11b, CD11c, CD103 and CX~3~CR1. In particular, CD103^+^ dendritic cells and CX~3~CR1^+^ CD11b^+^ cells have been well characterized in the murine intestine ([@B14]-[@B16]). Pre-cDCs (cDC precursors) give rise to CD103^+^dendritic cells whereas Ly6C^high^ monocytes differentiate into CX~3~CR1^+^ cells. Several studies have revealed that both CD103^+^ dendritic cells and CX~3~CR1^+^ cells are a heterogeneous population implicated in either protective immunity or immune tolerance.

CD103^+^ dendritic cell
-----------------------

CD103^+^ dendritic cells can stimulate CD4^+^ and CD8^+^ T cell proliferation ([@B17],[@B18]) and CD103^+^ dendritic cells activated by TLR ligands strongly induce cytotoxic T lymphocytes ([@B17]). In addition, IL-6-producing CD103^+^CD11b^+^ dendritic cells migrate to mesenteric lymph node via expression of CCR7 and induce Th17 development in a transcription factor IRF4-dependent manner ([@B19]-[@B21]) ([Fig. 1A](#F1){ref-type="fig"}). TLR5-activated CD103^+^ CD11b^+^CD11c^high^ dendritic cells induce Th1/Th17 responses ([@B22]). Moreover, recent study revealed that IL-23 production by TLR5^+^CD103^+^CD11b^+^ dendritic cells in response to flagellin promotes epithelial expression of RegIIIγ through induction of IL-22 production by innate lymphoid cells ([@B23]) ([Fig. 1B](#F1){ref-type="fig"}). Furthermore, CD103^+^CD11b^+^CD24^+^ dendritic cells have been reported to drive Th17 development by IL-23 production. Thus, CD103^+^CD11b^+^ dendritic cells can mediate the maintenance of gut homeostasis through promotion of protective immunity by inducing T cell activation and antimicrobial defense in the intestinal epithelial cells.

At steady state, IL-10-producing CD4^+^ T cells containing two subsets: Foxp3^+^ T~reg~ cells and type I regulatory T cells (Tr1 cells). CD103^+^CD11c^+^ dendritic cells have been reported to be responsible for immune tolerance to the intestinal antigens by promoting Foxp3^+^ T~reg~ cell differentiation through the production of retinoic acid and TGF-β ([@B12],[@B24],[@B25]) ([Fig. 1C](#F1){ref-type="fig"}). In addition, it has recently been clarified that one of the common probiotics, *Bifidobacterium breve* can induce Tr1 cell development via TLR2-dependent activation of CD103^+^ dendritic cells ([@B26]). *B. breve* activates intestinal CD103^+^ DCs to produce IL-10 and IL-27 via the TLR2/MyD88 pathway thereby inducing IL-10-producing Tr1 cells in the large intestine ([Fig. 1D](#F1){ref-type="fig"}). Oral *B. breve* administration ameliorated colitis through the induction of intestinal IL-10-producing Tr1 cells ([@B26]).

CX~3~CR1^intermediate^CD70^+^ CD11b^+^ dendritic cells
------------------------------------------------------

CX~3~CR1^+^ mononuclear cells have been identified as major populations in the intestinal lamina propria by using CX~3~CR1-GFP transgenic mice ([@B27]). To date, in the colonic lamina propria, several subsets of CX~3~CR1^+^ cell have been characterized, such as CD11c^-^CX~3~CR1^+^, CD11c^+^CX~3~CR1^+^CD68^+^F4/80^+^ and CD11c^+^CX~3~CR1^+^CD68^-^F4/80^-^ cell population ([@B15]). Studies have shown that CX~3~CR1^+^ cells can drive the induction of Th17 development ([@B28],[@B29]). In particular, CX~3~CR1^intermediate^ CD70^+^CD11b^+^ dendritic cells express a series of ATP receptors that can induce Th17 cell development ([@B28]) ([Fig. 2A](#F2){ref-type="fig"}). Administration of ATP to germ-free mice with few Th17 cells enhances the accumulation of Th17 cells in the lamina propria, indicating that commensal bacteria-derived ATP is responsible for initiation of Th17 cell development.

CX~3~CR1^+^ intestinal innate immune cells do not always induce pro-inflammatory responses, even though a part of these cells can enhance the differentiation of Th17 cells ([@B28],[@B29]). IL-10 derived from CX~3~CR1^+^ macrophage in a CX~3~CL1-dependent manner support the expansion of Foxp3^+^ T~reg~ cells ([@B30]). In addition, CX~3~CR1^+^ macrophages limit Th17 cells-dependent intestinal inflammation by controlling the bacterial clearance ([@B31]). In addition, recent study revealed that antigen cross-presentation by CX~3~CR1^+^ cells in the small intestinal lamina propria is responsible for differentiation of IL-10/IL-13/IL-9-expressing CD8^+^ T cells with ability to suppress antigen-specific activation of CD4^+^ T cells, leading to inhibition of intestinal inflammation ([@B32]).

CX~3~CR1^high^ regulatory myeloid cells
---------------------------------------

CX~3~CR1^high^CD11b^+^CD11c^+^ subset, which has been named regulatory myeloid (M~reg~) cells, has been identified to possess a negative regulatory function ([@B33]). M~reg~ cells are distributed in the intestinal lamina propria, suppress CD4^+^ T cell proliferation in a cell-cell contact-dependent manner, and contribute to the prevention of intestinal inflammation. M~reg~ cells preferentially associate with CD4^+^ T cells via highly expressed adhesion molecules such as ICAM-1 and VCAM-1, but do not activate CD4^+^ T cells owing to the IL-10/Stat3-dependent suppression of CD80/CD86 expression ([Fig. 2B](#F2){ref-type="fig"}). *LysMcre; Stat3^flox/flox^* mice, which spontaneously develop colitis, show defective M~reg~ cell function. Administration of wild-type M~reg~ cells to Stat3 mutant mice ameliorated intestinal inflammation, indicating that a dysfunction of M~reg~ cells is involved in the pathogenesis of IBD. Taken together, several subsets of CX~3~CR1^+^ innate immune cells contribute to both anti-inflammatory and pro-inflammatory responses in the intestine, suggesting that the disrupted functions of these cells lead to dysregulation of intestinal immune responses resulting in development of IBD.

Others
------

Intestinal CD11b^+^CD11c^-^ macrophages produce substantial amounts of IL-10 in response to microflora ([@B34]-[@B36]) ([Fig. 2C](#F2){ref-type="fig"}). IL-10 produced by intestinal macrophages limits the intestinal inflammation through the persistence of Foxp3 expression in T~reg~ cells ([@B37]). In addition, intestinal macrophages-derived IL-10 inhibits IL-12 and TNF-α production against the microbiota in intestinal myeloid cells in an IL-10/Stat3 signal-dependent manner. Consequently, IL-10-deficient mice and myeloid cell-specific Stat3 mutant mice (*LysM-cre; Stat3^flox/flox^*) spontaneously develop enteric inflammation.

Apart from CD103^+^ dendritic cells, CX~3~CR1^+^ cells and macrophages, E-cadherin-expressing dendritic cells, which highly express TLRs and produce colitogenic cytokines including IL-6 and IL-23, enhance the intestinal inflammation by increasing Th17 responses ([@B23]). Thus, several subsets of intestinal innate immune myeloid cells contribute to maintenance of gut homeostasis, and dysregulation of activities of these cells leads to development of IBD.

REGULATION OF IBD BY HUMAN MYELOID SUBSETS
==========================================

Numerous murine studies have shown that intestinal innate immune cells are heterogeneous and comprise several subtypes with different phenotypes and functional properties. Recently, studies have reported human counterpart to murine intestinal macrophages, CD103^+^ dendritic cells and CX~3~CR1^intermediate^ CD70^+^ dendritic cells.

Human intestinal macrophage
---------------------------

Recent studies have suggested that the intestinal macrophages play important roles in protecting host from invading pathogens and regulating excess immune responses to commensal bacteria by producing IL-10 ([Fig. 3A](#F3){ref-type="fig"}). Interestingly, numbers of CD14^+^ macrophage are increased in patients with CD and produce greater amounts of colitogenic cytokines including IL-6, IL-23 and TNF-α against microbiota than do healthy individuals ([@B38]). Furthermore, human intestinal CD14^+^ macrophage-derived IL-23 may enhance colitogenic IL-17 and IFN-γ-producing T cell differentiation, suggesting that abnormal innate immune responses by macrophages play a major role in the pathogenesis of IBD ([@B38]-[@B41]) ([Fig. 3B](#F3){ref-type="fig"}).

Human CD103^+^ dendritic cells
------------------------------

Similar to murine CD103^+^ dendritic cells, human CD103^+^ dendritic cells that can induce homing receptors such as CCR9 and integrin α4β7 on T cells have been reported ([@B18]). In addition, transcription factor IRF4-expressing CD103^+^CD141^-^ SIRPα^high^ dendritic cells have been clarified in the humane small intestine ([@B21]) ([Fig. 3A](#F3){ref-type="fig"}), suggesting that these cells might be equivalent to murine CD103^+^CD11b^+^ dendritic cells possessing the ability to enhance Th17 cell differentiation.

CD14^+^CD163^low^ cells
-----------------------

Several findings on human counterpart to the murine intestinal macrophages and CD103^+^ dendritic cells have been shown, as described above. Furthermore, it has recently been identified HLA-DR^high^CD14^+^CD163^low^ cells as equivalents of CX~3~CR1^intermediate^CD70^+^CD11b^+^ dendritic cells driving Th17 cell differentiation ([@B42]).

In the human intestinal mucosa, HLA-DR^high^Lin^-^ cells could be divided into CD14^+^CD163^low^, CD14^+^CD163^high^, CD14^-^ CD11c^low^, and CD14^-^CD11c^high^ subsets. CD14^+^CD163^low^ cells can induce Th17 differentiation by high expression of IL-6, IL-23p19, TNF-α and IL-1β, via TLR2, TLR4 and TLR5 signal pathway even in steady state ([Fig. 3A](#F3){ref-type="fig"}). In addition, CD14^+^ CD163^low^ cells produce a low level of IL-10. Recent study reported that murine CX~3~CR1^intermediate^ dendritic cells promoting Th17 polarization produce not only IL-6 and TNF-α, but also IL-10. In addition, CD14^+^CD163^low^ cells express both macrophage-related and dendritic cell-related marker as well as CX~3~CR1^intermediate^ dendritic cells, suggesting that CD14^+^CD163^low^ cells are the putative equivalents of CX~3~CR1^intermediat^ cells. Furthermore, the activity of CD14^+^CD163^low^ cells to drive Th17 differentiation is increased in the intestinal mucosa of patients with CD ([Fig. 3B](#F3){ref-type="fig"}), further suggesting that CD14^+^ CD163^low^ cells might play a crucial role in pathogenesis of CD.

CONCLUSION
==========

Recent advances have revealed crucial roles of innate immune cells for protection against foreign pathogens and immunological tolerance in mice. The aberrant activation of innate immunity in the intestinal mucosa can lead to development of several inflammatory diseases by triggering Th1/Th17 responses. Th1 and Th17 cells contribute to the protective responses to pathogens during physiological conditions in steady state, whereas excessive activation of these cells is responsible for intestinal inflammation. Thus, Foxp3^+^ T~reg~ cells abundantly exist in the intestinal mucosa and inhibit innate and adaptive immune responses for preventing intestinal inflammation.

To date, several studies have clarified human counterparts to the murine intestinal innate immune subsets inducing Th1/Th17 differentiation. Compared with innate inflammatory subsets, other subsets inducing Foxp3^+^ T~reg~ cells in the human intestinal mucosa remains poorly characterized. Thus, further studies to identify innate immune subsets driving Foxp3+T~reg~ cells in the human intestine may promote advances in therapeutic approaches for IBD.

A previous study showed that IL-10-producing Foxp3^+^CD4^+^ CD25^+^ cells accumulate at inflamed sites in patients with IBD ([@B43]), indicating that IBD is not simply a result of defective T~reg~ cell function. In *LysM-cre; Stat3^flox/flox^* mice, the severity of intestinal inflammation was improved by administration of wild-type M~reg~ cells. These findings raise the possibility that the impaired M~reg~ function is responsible for onset or/and progression of IBD. Accordingly, it will be important for the clinical application of M~reg~ cells for intestinal inflammation to determine whether M~reg~ cells are present in the human intestine and fully functional in patients with IBD.
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![Murine CD103^+^ dendritic cells. (A) IRF4^+^CD103^+^CD11b^+^ dendritic cells induce Th17 development through the production of IL-6. (B) IL-23-expressing TLR5^+^CD103^+^CD11b^+^ dendritic cells promote differentiation of Th1 and Th17 cells and induce antimicrobial peptide RegIIIg from epithelial cells through the induction of IL-22 by innate lymphoid cells (ILC). (C) CD103^+^CD11c^+^ dendritic cells induce differentiation of Foxp3^+^ T~reg~ cells through the production of retinoic acid and TGF-β. (D) *B. breve*enhances accumulation of Tr1 cells via TLR2 signaling-dependent activation of CD103^+^CD11c^+^ dendritic cells.](in-13-227-g001){#F1}

![Murine innate myeloid subsets. (A) CX~3~CR1^intermediate^CD70^+^CD11b^+^ dendritic cells can induce Th17 cell development in a commensal bacteria-derived ATP dependent manner. (B) M~reg~ cells tightly regulate Th17/Th1 cell proliferation in an IL-10/Stat3-dependent fashion. (C) Macrophages mediate sustained expression of Foxp3 in T~reg~ cells by producing IL-10. In addition, macrophage-derived IL-10 acts on intestinal macrophages, dendritic cells and neutrophils to inhibit colitogenic cytokine production including IL-12p40, TNF-α, IL-23 and IL-6, which contribute to the initiation of Th1/Th17 cell development.](in-13-227-g002){#F2}

![Human intestinal innate myeloid cells. (A) At steady state, CD14^+^ macrophages play important roles in maintaining immune tolerance by producing IL-10. In contrast, IRF4-expressing CD103^+^ CD141^-^SIRPα^high^ dendritic cells and CD14^+^CD163^low^ cells activate pro-inflammatory pathway for host defense through the promotion of Th17 development. (B) In patients with Crohn\'s disease, IL-23-expressing CD14^+^ macrophages enhance colitogenic IL-17 and IFN-γ-producing T cell differentiation and the activity of CD14^+^CD163^low^ cells to drive Th17 differentiation is increased.](in-13-227-g003){#F3}
